Found: 236
Select item for more details and to access through your institution.
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1384509
- By:
- Publication type:
- Article
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 6, p. 1931, doi. 10.1007/s00277-024-05704-0
- By:
- Publication type:
- Article
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 6, p. 938, doi. 10.1111/ejh.14188
- By:
- Publication type:
- Article
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1384509
- By:
- Publication type:
- Article
Ruxolitinib: A new hope for ventilator‐induced diaphragm dysfunction.
- Published in:
- Acta Physiologica, 2024, v. 240, n. 5, p. 1, doi. 10.1111/apha.14128
- By:
- Publication type:
- Article
Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01056-0
- By:
- Publication type:
- Article
Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1372810
- By:
- Publication type:
- Article
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 8, p. 1270, doi. 10.1002/cncr.35156
- By:
- Publication type:
- Article
Acute invasive fungal sinusitis with orbital tip syndrome in patients on long-term use of ruxolitinib: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
- Published in:
- Journal of Clinical Immunology, 2024, v. 44, n. 4, p. 1, doi. 10.1007/s10875-024-01684-y
- By:
- Publication type:
- Article
Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF.
- Published in:
- Journal of Clinical Immunology, 2024, v. 44, n. 4, p. 1, doi. 10.1007/s10875-024-01687-9
- By:
- Publication type:
- Article
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 379, doi. 10.1111/ejh.14124
- By:
- Publication type:
- Article
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
- Published in:
- Hematological Oncology, 2024, v. 42, n. 2, p. 1, doi. 10.1002/hon.3259
- By:
- Publication type:
- Article
Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii66, doi. 10.1093/bjd/ljad498.067
- By:
- Publication type:
- Article
Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii71, doi. 10.1093/bjd/ljad498.073
- By:
- Publication type:
- Article
Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 677, doi. 10.1007/s00277-023-05535-5
- By:
- Publication type:
- Article
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
- Published in:
- Breast Cancer Research, 2024, v. 26, p. 1, doi. 10.1186/s13058-024-01774-0
- By:
- Publication type:
- Article
Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 16, doi. 10.1111/bjh.19173
- By:
- Publication type:
- Article
Severe relapses of cutaneous T‐cell lymphoma after treatment of chronic graft‐versus‐host disease with ruxolitinib.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 1, p. e32, doi. 10.1111/jdv.19408
- By:
- Publication type:
- Article
ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1283034
- By:
- Publication type:
- Article
An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 12, p. 3325, doi. 10.1007/s00277-023-05476-z
- By:
- Publication type:
- Article
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 12, p. 3383, doi. 10.1007/s00277-023-05458-1
- By:
- Publication type:
- Article
The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 12, p. 3647, doi. 10.1007/s00277-023-05456-3
- By:
- Publication type:
- Article
Spectrophotometric Study of Charge-Transfer Complexes of Ruxolitinib with Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone: An Application to the Development of a Green and High-Throughput Microwell Method for Quantification of Ruxolitinib in Its Pharmaceutical Formulations
- Published in:
- Molecules, 2023, v. 28, n. 23, p. 7877, doi. 10.3390/molecules28237877
- By:
- Publication type:
- Article
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
- Published in:
- Acta Haematologica, 2023, v. 146, n. 6, p. 522, doi. 10.1159/000533875
- By:
- Publication type:
- Article
Janus kinase inhibitors for alopecia areata: A narrative review.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 6, p. 799, doi. 10.25259/IJDVL_1093_2022
- By:
- Publication type:
- Article
Topical ruxolitinib: A new treatment for vitiligo.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 11, p. 2222, doi. 10.1111/jdv.19162
- By:
- Publication type:
- Article
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 6, p. 635, doi. 10.1007/s40272-023-00594-7
- By:
- Publication type:
- Article
Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Successful treatment of systemic EBV-positive T-cell lymphoma of childhood using the ruxolitinib combined with L-DEP regimen chemotherapy followed by haploidentical allogeneic hematopoietic stem cell transplantation.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 10, p. 2955, doi. 10.1007/s00277-023-05298-z
- By:
- Publication type:
- Article
Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 10, p. 1102, doi. 10.1093/ced/llad188
- By:
- Publication type:
- Article
Neutrophils in STAT1 Gain-Of-Function Have a Pro-inflammatory Signature Which Is Not Rescued by JAK Inhibition.
- Published in:
- Journal of Clinical Immunology, 2023, v. 43, n. 7, p. 1640, doi. 10.1007/s10875-023-01528-1
- By:
- Publication type:
- Article
The role of therapy in the outcome of patients with myelofibrosis.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 18, p. 2828, doi. 10.1002/cncr.34851
- By:
- Publication type:
- Article
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
- Published in:
- Acta Haematologica, 2023, v. 146, n. 5, p. 397, doi. 10.1159/000510281
- By:
- Publication type:
- Article
Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 5, p. 577, doi. 10.1007/s40272-023-00577-8
- By:
- Publication type:
- Article
Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
- Published in:
- Annals of Pharmacotherapy, 2023, v. 57, n. 8, p. 948, doi. 10.1177/10600280221143748
- By:
- Publication type:
- Article
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 578, doi. 10.1002/hon.3071
- By:
- Publication type:
- Article
Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis.
- Published in:
- International Journal of Clinical Pharmacy, 2023, v. 45, n. 4, p. 830, doi. 10.1007/s11096-023-01569-x
- By:
- Publication type:
- Article
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01471-z
- By:
- Publication type:
- Article
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 2, p. 284, doi. 10.1111/bjh.18853
- By:
- Publication type:
- Article
Sex-Specific Protection of Endothelial Function after Vascular Ischemia/Reperfusion Injury by the Senomorphic Agent Ruxolitinib.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 14, p. 11727, doi. 10.3390/ijms241411727
- By:
- Publication type:
- Article
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.
- Published in:
- Frontiers in Endocrinology, 2023, p. 01, doi. 10.3389/fendo.2023.1141029
- By:
- Publication type:
- Article
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1211655
- By:
- Publication type:
- Article
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2<sup>V617F</sup> myeloproliferative neoplasms.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00875-x
- By:
- Publication type:
- Article
Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 1, p. 135, doi. 10.1111/bjh.18817
- By:
- Publication type:
- Article
A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 7, p. 976, doi. 10.3390/ph16070976
- By:
- Publication type:
- Article
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1212638
- By:
- Publication type:
- Article
An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.
- Published in:
- Science Translational Medicine, 2023, v. 15, n. 701, p. 1, doi. 10.1126/scitranslmed.abq7839
- By:
- Publication type:
- Article
396 Rapid, substantial and sustained reduction of itch in adults with atopic dermatitis applying ruxolitinib cream 1.5% (SCRATCH-AD).
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.021
- By:
- Publication type:
- Article